The importance of multimodal imaging in the diagnosis of AMD and geographic atrophy
The U.S. Food and Drug Administration (FDA) has approved a drug for the treatment of geographic atrophy (GA) for the first time, one of the advanced forms of dry age-related macular degeneration (AMD). The approval is considered a breakthrough in ophthalmology and finally gives patients hope of positively impacting the course of the disease.
